HR Execs on the Move

Stilla Technologies

www.stillatechnologies.com

 
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla`s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world`s first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Matthew Grow
Vice President of Global Marketing and Commercial Operations Profile

Similar Companies

Stop Heart Attack Dot Com

Stop Heart Attack Dot Com is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SEEPOINT TECHNOLOGY

SEEPOINT TECHNOLOGY is a Redondo Beach, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Camarillo Health Care District

Camarillo Health Care District is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Camarillo, CA. To find more information about Camarillo Health Care District, please visit www.camhealth.com

Bioatla

BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.

Signature Family Wealth

Signature is a Virginia-based multi-family office, offering clients comprehensive strategies and solutions for all aspects of their financial life. With assets under management in excess of $3.7 billion, Signature takes an intelligent approach to creating customized plans for their high net worth individuals and families.